Document Detail


Antianxiety effects of lorazepam in patients with cardiovascular symptomatology.
MedLine Citation:
PMID:  30766     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lorazepam was administered to 38 patients with moderate to severe anxiety associated with cardiovascular symptomatology. A comparable group of patients on placebo (35) served as controls in this 4-week study. Average dosage was 3 mg/day given as 2 mg in the evening and 1 mg in the morning. The Global response, Hamilton Anxiety Rating Scale scores, and 35-Item Self-Rating Scale scores showed lorazepam to be significantly more effective in relieving anxiety than placebo, both clinically and statistically. Adverse reactions were transient and tolerable, and were reported in only 2 patients on lorazepam.
Authors:
S Finkel
Related Documents :
9702646 - The effects of a psychological preparation program on anxiety in children and adolescen...
12008656 - Anxiety sensitivity as a specific and unique marker of anxious symptoms in youth psychi...
19281966 - How to handle anxiety: the effects of reappraisal, acceptance, and suppression strategi...
10880666 - Effects of anxiety and depression on 5-year mortality in 5,057 patients referred for ex...
22621696 - Intravenous ibuprofen: in adults for pain and fever.
21791006 - The controversial role of phosphodiesterase type 5 inhibitors in the treatment of prema...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  39     ISSN:  0160-6689     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  1978 Oct 
Date Detail:
Created Date:  1979-01-15     Completed Date:  1979-01-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  35-40     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Aged
Anti-Anxiety Agents / therapeutic use*
Anxiety Disorders / drug therapy*,  etiology
Cardiovascular Diseases / psychology*
Double-Blind Method
Female
Humans
Lorazepam / administration & dosage,  adverse effects,  therapeutic use*
Male
Middle Aged
Placebos
Psychiatric Status Rating Scales
Time Factors
Chemical
Reg. No./Substance:
0/Anti-Anxiety Agents; 0/Placebos; 846-49-1/Lorazepam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Studies with oral lorazepam in anxiety neurosis associated with depressive symptomatology.
Next Document:  The effect of lorazepam on hypertension-associated anxiety: a double-blind study.